Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 81, Issue 1, Pages 11-14Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2021-221406
Keywords
magnetic resonance imaging; spondylitis; ankylosing; tumour necrosis factor inhibitors; etanercept; biological therapy
Categories
Ask authors/readers for more resources
Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease primarily affecting the axial skeleton, with treatments aimed at reducing new bone formation to slow disease progression.
Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease that manifests primarily in the axial skeleton, initially mostly in the sacroiliac joints (SIJ), usually later spreading to the spine. The disease is characterised by inflammation and new bone formation which are mainly assessed by conventional radiography (CR) and magnetic resonance imaging (MRI). Tumour necrosis factor inhibitors (TNFi) and interleukin-17 antagonists have been shown to be efficacious and efficient in patients with axSpA. This treatment seems to also inhibit structural damage, for example, retard radiographic progression. Indeed, a reduction of new bone formation in the spine, as assessed by CR, has been reported to occur after at least 2 years of therapy with TNFi. Recently, a reduction of erosions and ankylosis in the SIJ has also been observed in axSpA patients treated with etanercept and filgotinib. In this narrative review, we discuss the limited significance of such findings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available